Intersect ENT Quote - XENT

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

28.25

Bid

28.16

Ask

28.36

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Previous Close

28.25

Open

Last Trade

Last Trade Time

Average Volume (3m)

Financial Volume

VWAP

Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare...

Intersect ENT Reports Third Quarter 2021 Financial Results

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter...

First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc. PR Newswire NEW YORK, Aug. 9, 2021 NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating...

Intersect ENT Shares Rise on Medtronic Takeover Deal

By Colin Kellaher Shares of Intersect ENT Inc. rose more than 12% on Friday after the drug-delivery company agreed to be acquired by medical-technology giant Medtronic PLC. Dublin-based Medtronic...

Medtronic to Buy Intersect ENT for $28.25/Share

By Colin Kellaher Medtronic PLC on Friday said it agreed to buy Intersect ENT Inc. in an all-cash deal with an implied enterprise value of about $1.1 billion. Dublin-based medical-technology...

Intersect ENT Reports Second Quarter 2021 Financial Results

Medtronic to Acquire Intersect ENT

Medtronic to Acquire Intersect ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio Canada NewsWire DUBLIN and MENLO PARK, Calif., Aug. 6...

U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis

VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LAESSEALSQ Corporation	US$ 1.1406 (99.75%)	225.46M
AMPGAmplitech Group Inc	US$ 1.9001 (91.52%)	201.88M
CADLCandel Therapeutics Inc	US$ 7.7401 (67.90%)	100.61M
JZXNJiuzi Holdings Inc	US$ 1.792 (60.00%)	2.56M
LDTCLeddarTech Holdings Inc	US$ 1.81 (49.59%)	75.14M
SFHGSamfine Creation Holdings Group Ltd	US$ 3.04 (-85.59%)	10.2M
CLRBCellectar Biosciences Inc	US$ 0.3039 (-76.26%)	37.51M
QTTBQ32 Bio Inc	US$ 6.0291 (-75.30%)	3.39M
TFFPTFF Pharmaceuticals Inc	US$ 0.1639 (-45.78%)	3.5M
MARXMars Acquisition Corporation	US$ 7.24 (-33.33%)	54.57k
RGTIRigetti Computing Inc	US$ 7.38 (13.71%)	307.29M
LAESSEALSQ Corporation	US$ 1.1406 (99.75%)	223.51M
AMPGAmplitech Group Inc	US$ 1.9001 (91.52%)	200.45M
NVDANVIDIA Corporation	US$ 139.31 (3.14%)	182.44M
LCIDLucid Group Inc	US$ 2.44 (3.39%)	110.58M